Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer

Abstract

Objective: To determine the association of 68 Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancer patients.

Methods: A total of 148 consecutive patients mean age: 69.3 ± 7.8 years with advanced prostate cancer who underwent 68 Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68 Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded.

Results: Multivariate regression analysis revealed that Level 1 LN SUV/Liver SUV ratios > 2.17 (OR 4.262; 95% CI 1.104-16.453, p = 0.035), bone SUV > 10.7(OR 23.650; 95% CI 4.056-137.888, p < 0.001), bone SUV/spleen SUV ratio > 1.842 (OR 25.324; 95% CI 4.204-152.552, p < 0.001), highest SUV_max/liver SUV ratio > 2.32 (OR 19.309; 95% CI 1.730-209.552, p = 0.016) and highest SUV_max/spleen SUV ratio > 1.842 (OR 22.354; 95% CI 2.637-189.493, p = 0.004) were significant in the determination of increased mortality risk in advanced prostate cancer patients.

Conclusion: Our findings, for the first time in literature, provided evidence on potential utility of tracer uptake (SUV) cut-off values on 68 Ga-PSMA PET/CT in identification of the survival outcome of patients with metastatic disease and thereby in assisting in the selection of individualized therapeutic strategies tailored to the expected prognosis.

Keywords: 68 Ga-PSMA-I&T PET/CT; Bone; Lymph node; Metastasis; Prostate cancer; SUV.